| Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin -> Monitor Keywords |
|
|
 
Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotoninRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai, Hetero Ring Is Six-membered Consisting Of Three Nitrogens And Three Carbon Atoms, Asymmetrical (e.g., 1,2,4-triazine, Etc.), Polycyclo Ring System Having The Hetero Ring As One Of The CyclosUse of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20060063766, Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin. Brief Patent Description - Full Patent Description - Patent Application Claims
[0001] This invention relates to novel compounds, processes for their preparation, pharmaceutical formulations containing them and their use in therapy. [0002] Inflammation is a primary response to tissue injury or microbial invasion and is characterised by leukocyte adhesion to the endothelium, diapedesis and activation within the tissue. Leukocyte activation can result in the generation of toxic oxygen species (such as superoxide anion), and the release of granule products (such as peroxidases and proteases). Circulating leukocytes include neutrophils, eosinophils, basophils, monocytes and lymphocytes. Different forms of inflammation involve different types of infiltrating leukocytes, the particular profile being regulated by the profile of adhesion molecule, cytokine and chemotactic factor expression within the tissue. [0003] The primary function of leukocytes is to defend the host from invading organisms, such as bacteria and parasites. Once a tissue is injured or infected, a series of events occurs which causes the local recruitment of leukocytes from the circulation into the affected tissue. Leukocyte recruitment is controlled to allow for the orderly destruction and phagocytosis of foreign or dead cells, followed by tissue repair and resolution of the inflammatory infiltrate. However in chronic inflammatory states, recruitment is often inappropriate, resolution is not adequately controlled and the inflammatory reaction causes tissue destruction. There is increasing evidence that the bronchial inflammation which is characteristic of asthma represents a specialised form of cell-mediated immunity, in which cytokine products, such as IL-4 and IL-5 released by T-helper 2 (Th2) lymphocytes, orchestrate the accumulation and activation of granulocytes, in particular eosinophils and to a lesser extent basophils. Through the release of cytotoxic basic proteins, pro-inflammatory mediators and oxygen radicals, eosinophils generate mucosal damage and initiate mechanisms that underlie bronchial hyperreactivity. Therefore, blocking the recruitment and activation of Th2 cells and eosinophils is likely to have anti-inflammatory properties in asthma. In addition, eosinophils have been implicated in other disease types such as rhinitis, eczema, irritable bowel syndrome and parasitic infections. [0004] Chemokines are a large family of small proteins which are involved in trafficking and recruitment of leukocytes (for review see Luster, New Eng. J. Med., 338, 436-445 (1998)). They are released by a wide variety of cells and act to attract and activate various cell types, including eosinophils, basophils, neutrophils, macrophages, T and B lymphocytes. There are two major families of chemokines, CXC-(.alpha.) and CC-(.beta.) chemokines, classified according to the spacing of two conserved cysteine residues near to the amino terminus of the chemokine proteins. Chemokines bind to specific cell surface receptors belonging to the family of G-protein-coupled seven transmembrane-domain proteins (for review see Luster, 1998). Activation of chemokine receptors results in, amongst other responses, an increase in intracellular calcium, changes in cell shape, increased expression of cellular adhesion molecules, degranulation and promotion of cell migration (chemotaxis). [0005] To date a number of CC chemokine receptors have been identified and of particular importance to the current invention is the CC-chemokine receptor-3 (CCR-3), which is predominantly expressed on eosinophils, and also on basophils, mast cells and Th2 cells. Chemokines that act at CCR-3, such as RANTES, MCP-3 and MCP-4, are known to recruit and activate eosinophils. Of particular interest are eotaxin and eotaxin-2, which specifically bind to CCR-3. The localization and function of CCR-3 chemokines indicate that they play a central role in the development of allergic diseases such as asthma. Thus, CCR-3 is specifically expressed on all the major cell types involved in inflammatory allergic responses. Chemokines that act at CCR-3 are generated in response to inflammatory stimuli and act to recruit these cell types to sites of inflammation, where they cause their activation (e.g. Griffiths et al., J. Exp. Med., 179, 881-887 (1994), Lloyd et al., J. Exp. Med., 191, 265-273 (2000)). In addition, anti-CCR-3 monoclonal antibodies completely inhibit eotaxin interaction with eosinophils (Heath, H. et al., J. Clin. Invest. 99 (2), 178-184 (1997)), while an antibody for the CCR-3 specific chemokine, eotaxin, reduced both bronchial hyperreactivity and lung eosinophilia in an animal model of asthma (Gonzalo et al., J. Exp. Med., 188, 157-167 (1998). Thus, many lines of evidence indicate that antagonists at the CCR-3 receptor are very likely to be of therapeutic use for the treatment of a range of inflammatory conditions. [0006] In addition to a key role in inflammatory disorders, chemokines and their receptors also play a role in infectious disease. Mammalian cytomegaloviruses, herpes viruses and pox viruses express chemokine receptor homologues, which can be activated by human CC chemokines such as RANTES and MCP-3 receptors (for review see Wells and Schwartz, Curr. Opin. Biotech., 8, 741-748, 1997). In addition, human chemokine receptors, such as CXCR-4, CCR-5 and CCR-3, can act as co-receptors for the infection of mammalian cells by microbes such as human immunodeficiency viruses (HIV). Thus, chemokine receptor antagonists, including CCR-3 antagonists, may be useful in blocking infection of CCR-3 expressing cells by HIV or in preventing the manipulation of immune cellular responses by viruses such as cytomegaloviruses. [0007] International Patent Application publication number WO 01/24786 (Shionogi & Co. Ltd.) discloses certain aryl and heteroaryl derivatives for treating diabetes. WO 00/69830 (Torrey Pines Institute for Molecular Studies) discloses certain diazacyclic compounds, and libraries containing them, for biological screening. WO 00/18767 (Neurogen Corporation) discloses certain piperazine derivatives as dopamine D4 receptor antagonists. U.S. Pat. No. 6,031,097 and WO 99/21848 (Neurogen Corporation) discloses certain aminoisoquinoline derivatives as dopamine receptor ligands. WO 99/06384 (Recordati Industria Chimica) discloses piperazine derivatives useful for the treatment of neuromuscular dysfunction of the lower urinary tract. WO 98/56771 (Schering Aktiengesellschaft) discloses certain piperazine derivatives as anti-inflammatory agents. WO 97/47601 (Yoshitomi Pharmaceutical Industries Ltd.) discloses certain fused heterocyclic compounds as dopamine D-receptor blocking agents. WO 96/39386 (Schering Corporation) discloses certain piperidine derivatives as neurokinin antagonists. WO 96/02534 (Byk Gulden Lomberg Chemische Fabrik GmbH) discloses certain piperazine thiopyridines useful for controlling helicobacter bacteria. WO 95/32196 (Merck Sharp & Dohme Limited) discloses certain piperazine, piperidine, and tetrahydropyridine derivatives as 5-HT1D-alpha antagonists. U.S. Pat. No. 5,389,635 (E.I. Du Pont de Nemours and Company) discloses certain substituted imadazoles as angiotensin-II antagonists. European Patent Application publication number 0 306 440 (Schering Aktiengesellschaft) discloses certain imidazole derivatives as cardiovascular agents. [0008] A novel group of compounds has now been found which are CCR-3 antagonists. These compounds block the migration/chemotaxis of eosinophils and thus possess anti-inflammatory properties. These compounds are therefore of potential therapeutic benefit, especially in providing protection from eosinophil, basophil mast cell and Th2-cell-induced tissue damage in diseases where such cell types are implicated, particularly allergic diseases, including but not limited to bronchial asthma, allergic rhinitis and atopic dermatitis. [0009] Thus, according to one aspect of the invention, there are provided compounds of formula (I): wherein: [0010] R.sup.1 represents substituted or unsubstituted heteroaryl; [0011] Y represents --(CR.sub.naR.sub.nb).sub.n--; [0012] R.sub.na and R.sub.nb are each independently hydrogen or C.sub.1-6alkyl; [0013] n is an integer from 0 to 5; [0014] R.sup.2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; [0015] R.sup.3 and R.sup.4 each independently represent hydrogen or C.sub.1-6alkyl; [0016] R.sup.7 represents hydrogen or C.sub.1-6alkyl; [0017] R.sup.8 represents hydrogen or C.sub.1-6alkyl; and salts and solvates thereof; with the proviso that the following compounds are excluded; [0018] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(pyridin-3-ylm- ethyl)urea; [0019] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(6-methoxypyridin-3-- yl)methyl]urea; [0020] 5-({[({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)carbonyl]-amino- }methyl)nicotinamide; [0021] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(1H-indol-5-ylmethyl)- urea; [0022] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(1H-indol-4-ylmethyl)- urea; [0023] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(5-methylisoxazol-3-- yl)methyl]urea; [0024] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(thien-2-ylmethyl)ure- a; [0025] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(2-thien-2-- ylethyl)urea; [0026] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-({5-[(dimethylamino)m- ethyl]-2-furyl}methyl)urea; [0027] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(3-methoxyisothiazol- -5-yl)methyl]urea; [0028] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(4-methyl-1,3-thiazo- l-2-yl)methyl]urea; [0029] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(1,3-thiazol-2-ylmeth- yl)urea; [0030] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(2-methyl-1,3-thiazo- l-4-yl)methyl]urea; [0031] methyl 2-({[({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)carbonyl]-amino- }-methyl)-4-methyl-1,3-thiazole-5-carboxylate; [0032] N-[(5-amino-1-phenyl-1H-pyrazol-4-yl)methyl]-N'-{[4-(3,4-dichlorobenzyl)-- morpholin-2-yl]methyl}urea; [0033] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(1H-pyrrolo[2,3-b]pyr- idin-3-ylmethyl)urea; [0034] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-({5-[(dimethylamino)-- methyl]thien-2-yl}methyl)urea; [0035] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(2-furylmethyl)urea; [0036] N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(2-methyl-2H-- tetraazol-5-yl)methyl]urea; [0037] N-{[3-(4-chlorophenyl)isoxazol-5-yl]methyl}-N'-{[(2S)-4-(3,4-dichlorobenz- yl)-morpholin-2-yl]methyl}urea; [0038] N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(2-methyl-2H-te- traazol-5-yl)methyl]urea; [0039] N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[(4-methyl-1,3-t- hiazol-2-yl)methyl]urea; [0040] N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(1,3-thiazol-2-y- lmethyl)-urea, and; [0041] N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-{[3-(4-methoxyph- enyl)-isoxazol-5-yl]methyl}urea. [0042] Examples of the heteroaryl group, R.sup.1, include benzofuranyl, benzimidazolyl, imidazolyl, pyridyl, pyrimidinyl, thiazolyl, thiophenyl, furanyl, pyrazinyl, tetrazolyl, triazolyl, oxadiazolyl, isoxazolyl, oxazolyl, and pyrazolyl. When R.sup.1 is substituted heteroaryl, suitable substituents include formamido; morpholino C.sub.1-6alkyl; C.sub.3-8cycloalkyl C.sub.1-6alkyl; C.sub.3-8cycloalkyl C.sub.1-6alkylaminocarbonyl; aryl; C.sub.1-6alkoxycarbonyl C.sub.1-6alkyl; perhaloC.sub.1-6alkyl; cyanoC.sub.1-6alkyl; carboxy; R.sup.5R.sup.6NC(O)--, wherein R.sup.5 and R.sup.6 may each independently represent hydrogen or C.sub.1-6alkyl, or R.sup.5 and R.sup.6 may represent a --(CH.sub.2).sub.p-- group wherein p is an integer from 3 to 7 so that, together with the nitrogen atom to which they are attached, a 4 to 8-membered heterocyclyl ring is formed which heterocyclyl ring may contain a further heteroatom selected from N and O; C.sub.3-8 cycloalkylaminocarbonyl; amino; C.sub.1-6-alkylsulphonylamino; C.sub.1-6alkylcarbonyl; C.sub.1-6alkyl; C.sub.1-6alkoxycarbonyl; unsubstituted heteroaryl; heteroaryl substituted with C.sub.1-6alkyl, halo, C.sub.1-6alkoxy, or hydroxy; halo; C.sub.1-6alkoxy; nitro; C.sub.1-6alkylsulphonyl; hydroxy; C.sub.1-6alkoxyC.sub.1-6alkyl; C.sub.1-6alkylthio; (mono- and-di-C.sub.1-6alkyl)aminoC.sub.0-6alkyl; and C.sub.1-6alkylcarbonylamino. [0043] When R.sup.1 is substituted by unsubstituted or substituted heteroaryl, examples of said heteroaryl group include isoxazolyl, triazolyl, and oxadiazolyl. [0044] Suitably, R.sup.1 is unsubstituted benzimidazolyl, unsubstituted benzofuranyl, unsubstituted or substituted imidazolyl, unsubstituted or substituted pyridyl, unsubstituted or substituted pyrimidinyl, unsubstituted or substituted isoxazolyl, unsubstituted or substituted pyrazinyl, unsubstituted or substituted tetrazolyl, unsubstituted or substituted triazolyl, unsubstituted or substituted pyrazolyl, unsubstituted or substituted furanyl, unsubstituted or substituted thiazolyl, unsubstituted or substituted thiophenyl, unsubstituted or substituted oxadiazolyl, or unsubstituted or substituted oxazolyl [0045] When R.sup.1 is substituted imidazolyl, suitable substituents include aryl and C.sub.1-6alkyl. Continue reading about Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin... Full patent description for Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin or other areas of interest. ### Previous Patent Application: Novel compounds Next Patent Application: Phthalazinone derivatives Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin patent info. IP-related news and info Results in 0.24225 seconds Other interesting Feshpatents.com categories: Novartis , Pfizer , Philips , Polaroid , Procter & Gamble , 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
